AstrZeneca/Daiichi Sankyo Enhertu: ‘Impressive’ new data in HER2 breast cancer

 

• AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF +2.5%) have reported updated results from Phase 2 trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy and durable responses in patients with HER2-positive metastatic breast cancer.
• Updated data demonstrated that patients treated with Enhertu achieved an objective response rate (ORR) of 61.4% and a median duration (DoR) of response of 20.8 months.
• In addition, median progression-free survival was 19.4 months, with an exploratory landmark analysis of overall survival also showed that an estimated 74% of patients remained alive at 18 months.
• Prior analysis at 11.1 months of follow-up found an ORR of 60.9% and a median DoR of 14.8 months, as well as a median PFS of 16.4 months.
• The overall safety and tolerability profiles of Enhertu were consistent with what has been previously reported, with few additional treatment discontinuations due to adverse events with longer treatment duration.
• AZ and Daiichi are continuing to study Enhertu in a number of ongoing Phase 3 trials in patients with HER2-expressing metastatic breast cancer.
• https://seekingalpha.com/news/3643387-azn-daiichi-sankyo-enhertu-scores-impressive-new-data-in-her2-breast-cancer-study